IIntegra LifeSciences develops regenerative medicine and medical devices to help tissue repair. Its core products include tissue regeneration scaffolds that are implanted on wounds to provide a temporary matrix for cells to grow, guiding the body’s tissue to replace damaged skin and other tissues, and then integrate into healing. The company differentiates itself through a diversified portfolio that includes neurosurgical devices, wound care products, and specialized surgical instruments obtained through acquisitions, spanning multiple surgical domains. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Plainsboro Township, NJ
Founded
1989
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1.4B
Above
Industry Average
Funded Over
3 Rounds
Integra LifeSciences shares have returned 30.0% over the past year, including dividends. They cost $11.3 on November 4, 2025, and now trade at $14.82. Bulls set fair value at $15.88, citing ageing demand and product relaunches in neurosurgery and advanced wound care. Bears set it at $10, citing reimbursement cuts, FDA warnings and shipping holds that could keep revenue growth near 3.2% and profit margin at 1.3%. Third-quarter 2026 revenue was $411.2 million and net income $14.9 million. Net margin moved from a 1.3% loss a year earlier to a 3.6% profit. The July 2026 Cincinnati flood and related investigations keep operational risks alive. The company carries about $1.6 billion of net debt and plans to refinance at an estimated 100 to 200 basis points higher rate.
Integra LifeSciences returned to profit in the third quarter of 2026, reporting net income of $14.85 million against a loss a year earlier. Sales were $411.18 million, and diluted earnings per share from continuing operations were $0.19. The company guided fourth quarter revenue of $413 million to $433 million, a reported decline of 5.2% to 0.5%. It also plans to showcase neurosurgery technologies at a major clinical meeting. Risks remain, including high leverage, upcoming refinancing, product relaunches, quality costs, and flood-related disruption. Analysts project revenue of about $1.8 billion and earnings of roughly $136.1 million by 2029.
Integra LifeSciences shares fell about 11% in the first full session after its third-quarter 2026 results, as investors focused on refinancing worries and a high price-to-earnings ratio. Revenue rose to $411.2 million from $402.1 million a year earlier. The company posted a net profit of $14.9 million, against a $5.4 million loss, or basic earnings per share of $0.19. Operating cash flow reached $96 million, and net leverage fell to 3.8x. Net debt remains about $1.6 billion. Integra plans to refinance through new $450 million 9.5% notes, at an estimated 100 to 200 basis points higher rate. It also forecasts higher interest costs in 2027 and a softer fourth-quarter organic outlook.
Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.
Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Plainsboro Township, NJ
Founded
1989
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs